The biotech pharmaceutical company HIPRA will initiate a study to evaluate the safety and immune response of the COVID-19 vaccine BIMERVAX® when co-administered (one in each arm) with the seasonal influenza vaccine in adults 65 years of age or older who were first vaccinated against COVID-19 with an mRNA vaccine. The clinical trial has been authorised by the Spanish Agency for Medicines and Health Products (AEMPS).
The study will involve 300 volunteers and will be conducted in eight hospitals in Spain: Hospital Clínic Barcelona (Barcelona), Hospital Dr. Josep Trueta (Girona), Hospital Germans Trias i Pujol (Badalona), Hospital Clínico Universitario de Valladolid (Valladolid), HM Modelo (A Coruña), Hospital de Santiago (Santiago de Compostela), Hospital Regional de Málaga (Málaga) and CAP Centelles (Centelles, Barcelona). The clinical trial will last 2 months and each volunteer will have to visit the hospital 3 times. Each hospital has set up a space on its website so that those interested can register for the study.
The study will be evaluated by the Ethics Committee of HM Hospitals and the Spanish Agency of Medicines and Health Products (AEMPS).
Hospitals
Hospital Dr. Josep Trueta de Girona:
Hospital Clínic Barcelona:
634 264 791
ABS Centelles:
93 881 04 85
Hospital Regional de Málaga:
preventiva.hrmal.sspa@juntadeandalucia.es
